Venbio Global Strategic Fund Iii, L.p. - Net Worth and Insider Trading

Venbio Global Strategic Fund Iii, L.p. Net Worth

The estimated net worth of Venbio Global Strategic Fund Iii, L.p. is at least $32 Million dollars as of 2024-08-24. Venbio Global Strategic Fund Iii, L.p. is the 10% Owner of Artiva Biotherapeutics Inc and owns about 1,936,637 shares of Artiva Biotherapeutics Inc (ARTV) stock worth over $19 Million. Venbio Global Strategic Fund Iii, L.p. is the of Ventyx Biosciences Inc and owns about 5,011,536 shares of Ventyx Biosciences Inc (VTYX) stock worth over $11 Million. Venbio Global Strategic Fund Iii, L.p. is also the 10% Owner of Elevation Oncology Inc and owns about 1,905,430 shares of Elevation Oncology Inc (ELEV) stock worth over $2 Million. Details can be seen in Venbio Global Strategic Fund Iii, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Venbio Global Strategic Fund Iii, L.p. has not made any transactions after 2024-07-22 and currently still holds the listed stock(s).

Transaction Summary of Venbio Global Strategic Fund Iii, L.p.

Venbio Global Strategic Fund Iii, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Venbio Global Strategic Fund Iii, L.p. owns 3 companies in total, including Elevation Oncology Inc (ELEV) , Ventyx Biosciences Inc (VTYX) , and RayzeBio inc (RYZB) .

Click here to see the complete history of Venbio Global Strategic Fund Iii, L.p.’s form 4 insider trades.

Insider Ownership Summary of Venbio Global Strategic Fund Iii, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
ELEV	Elevation Oncology Inc	2022-05-25	10 percent owner
VTYX	Ventyx Biosciences Inc	2021-10-25	10 percent owner & other: See Remarks
RYZB	RayzeBio inc	2023-09-14	10 percent owner

Venbio Global Strategic Fund Iii, L.p. Latest Holdings Summary

Venbio Global Strategic Fund Iii, L.p. currently owns a total of 3 stocks. Among these stocks, Venbio Global Strategic Fund Iii, L.p. owns 1,936,637 shares of Artiva Biotherapeutics Inc (ARTV) as of July 22, 2024, with a value of $19 Million and a weighting of 60.08%. Venbio Global Strategic Fund Iii, L.p. owns 5,011,536 shares of Ventyx Biosciences Inc (VTYX) as of October 25, 2021, with a value of $11 Million and a weighting of 35.14%. Venbio Global Strategic Fund Iii, L.p. also owns 1,905,430 shares of Elevation Oncology Inc (ELEV) as of May 25, 2022, with a value of $2 Million and a weighting of 4.78%.

Latest Holdings of Venbio Global Strategic Fund Iii, L.p.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ARTV	Artiva Biotherapeutics Inc	2024-07-22	1,936,637	10.00	19,366,370
VTYX	Ventyx Biosciences Inc	2021-10-25	5,011,536	2.26	11,326,071
ELEV	Elevation Oncology Inc	2022-05-25	1,905,430	0.81	1,541,112

Holding Weightings of Venbio Global Strategic Fund Iii, L.p.

Venbio Global Strategic Fund Iii, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Venbio Global Strategic Fund Iii, L.p. has made a total of 1 transactions in Artiva Biotherapeutics Inc (ARTV) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Artiva Biotherapeutics Inc is the acquisition of 416,666 shares on July 22, 2024, which cost Venbio Global Strategic Fund Iii, L.p. around $5 Million.

According to the SEC Form 4 filings, Venbio Global Strategic Fund Iii, L.p. has made a total of 1 transactions in Ventyx Biosciences Inc (VTYX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Ventyx Biosciences Inc is the acquisition of 312,500 shares on October 25, 2021, which cost Venbio Global Strategic Fund Iii, L.p. around $5 Million.

According to the SEC Form 4 filings, Venbio Global Strategic Fund Iii, L.p. has made a total of 1 transactions in Elevation Oncology Inc (ELEV) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Elevation Oncology Inc is the sale of 702,737 shares on May 25, 2022, which brought Venbio Global Strategic Fund Iii, L.p. around $3 Million.

Insider Trading History of Venbio Global Strategic Fund Iii, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Venbio Global Strategic Fund Iii, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Venbio Global Strategic Fund Iii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Venbio Global Strategic Fund Iii, L.p. is -20.84%. GuruFocus also compares Venbio Global Strategic Fund Iii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Venbio Global Strategic Fund Iii, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Venbio Global Strategic Fund Iii, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Venbio Global Strategic Fund Iii, L.p.

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-4.12
Relative Return to S&P 500(%)	-5.66

Venbio Global Strategic Fund Iii, L.p. Ownership Network

Ownership Network List of Venbio Global Strategic Fund Iii, L.p.

No Data

Ownership Network Relation of Venbio Global Strategic Fund Iii, L.p.

Venbio Global Strategic Fund Iii, L.p. Owned Company Details

What does Elevation Oncology Inc do?

Who are the key executives at Elevation Oncology Inc?

Venbio Global Strategic Fund Iii, L.p. is the 10 percent owner of Elevation Oncology Inc. Other key executives at Elevation Oncology Inc include CHIEF FINANCIAL OFFICER Tammy Furlong , 10 percent owner Robert J Adelman , and 10 percent owner Venbio Global Strategic Gp Iii, L.p. .

Elevation Oncology Inc (ELEV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Elevation Oncology Inc (ELEV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Elevation Oncology Inc (ELEV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Elevation Oncology Inc (ELEV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Elevation Oncology Inc Insider Transactions

No Available Data

What does Ventyx Biosciences Inc do?

Who are the key executives at Ventyx Biosciences Inc?

Venbio Global Strategic Fund Iii, L.p. is the 10 percent owner & other: See Remarks of Ventyx Biosciences Inc. Other key executives at Ventyx Biosciences Inc include director & Chief Executive Officer Raju Mohan , Chief Financial Officer Martin Auster , and Chief Scientific Officer John Nuss .

Ventyx Biosciences Inc (VTYX) Insider Trades Summary

Over the past 18 months, Venbio Global Strategic Fund Iii, L.p. made no insider transaction in Ventyx Biosciences Inc (VTYX). Other recent insider transactions involving Ventyx Biosciences Inc (VTYX) include a net sale of 773,232 shares made by Nsv Partners Iii Lp , a net sale of 773,232 shares made by Somu Subramaniam , and a net sale of 273,172 shares made by Raju Mohan .

In summary, during the past 3 months, insiders sold 0 shares of Ventyx Biosciences Inc (VTYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,372,600 shares of Ventyx Biosciences Inc (VTYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 2,372,600 shares.

Ventyx Biosciences Inc (VTYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ventyx Biosciences Inc Insider Transactions

No Available Data

What does RayzeBio inc do?

Who are the key executives at RayzeBio inc?

Venbio Global Strategic Fund Iii, L.p. is the 10 percent owner of RayzeBio inc. Other key executives at RayzeBio inc include 10 percent owner Viking Global Investors Lp , 10 percent owner Viking Global Opportunities Drawdown (aggregator) Lp , and 10 percent owner Goodman Corey S .

RayzeBio inc (RYZB) Insider Trades Summary

Over the past 18 months, Venbio Global Strategic Fund Iii, L.p. made no insider transaction in RayzeBio inc (RYZB). Other recent insider transactions involving RayzeBio inc (RYZB) include a net purchase of 2,777,778 shares made by Viking Global Investors Lp , and a net purchase of 472,222 shares made by Maha Katabi .

In summary, during the past 3 months, insiders sold 0 shares of RayzeBio inc (RYZB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of RayzeBio inc (RYZB) were sold and 3,250,000 shares were bought by its insiders, resulting in a net purchase of 3,250,000 shares.

RayzeBio inc (RYZB)'s detailed insider trading history can be found in Insider Trading Tracker table.

RayzeBio inc Insider Transactions

No Available Data

Venbio Global Strategic Fund Iii, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Venbio Global Strategic Fund Iii, L.p.. You might contact Venbio Global Strategic Fund Iii, L.p. via mailing address: 1700 Owens Street, Suite 595, San Francisco Ca 94158.

Discussions on Venbio Global Strategic Fund Iii, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.